Application No.: 10/593,259

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-10 (Cancelled).

11. (Currently Amended) A pharmaceutical composition comprising at least one compound of formula (C) or (D) and a pharmaceutically acceptable carrier which is useful in a medicine

wherein -X' is

m is 0 or 1;

Y' is

Q is CH or N;

K is S or O;

v is 0, 1, or 2;

R⁶ is CO₂H, CO₂Alkyl, CO₂Aryl, CO₂NH₂, CO₂Aralkyl, SO₃H, SO₂NH₂, PO(OH)₂, 1-H-tetrazolyl, CHO, COCH₃, CH₂OH, NH₂, NHAlkyl, N(Alkyl)Alkyl', OCH₃, CH₂OCH₃, SH, F, Cl, Br, I, CH₃, CH₂CH₃, CN, or CF₃;

R⁷, independently from R⁶, is H, CH₃, CH₂CH₃, CF₃, F, Cl, Br, I, CN, or NO₂;
R⁸, independently from R⁶ and R⁷, is H, CH₃, CH₂CH₃, CF₃, F, Cl, Br, I, CN, NO₂, or R⁶;

R^{9a} is H, NO₂, CF₃, F, CI, Br, I, CN, CH₃, OCH₃, SH, or NH₂;

R^{9b}, independently from R^{9a}, is H, NO₂, CF₃, F, Cl, Br, I, CN, CH₃, OCH₃, SH, or NH₂;

R¹⁰ is CO₂H, CO₂alkyl, CO₂aryl, CO₂NH₂, CO₂aralkyl, CH₂SO₃H, CH₂SO₂NH₂, CH₂PO(OH)₂, 1-H-tetrazolyl, CHO, COCH₃, CH₂OH, CH₂NH₂, CH₂NHalkyl, CH₂N(alkyl)alkyl', CH₂OCH₃, or CH₂SH;

R¹¹ is CO₂H, CO₂alkyl, CO₂aryl, CO₂NH₂, CO₂aralkyl, SO₃H, SO₂NH₂, PO(OH)₂, 1-H-tetrazolyl, CHO, COCH₃, OH, NH₂, NHalkyl, N(alkyl)alkyl', OCH₃, or SH; s is 1;

t is 0, 1, or 2;

-W- is -(CH₂-)_v, cis-CH=CH- or trans-CH=CH-, and v is 0,1,or 2;

in case that R^6 is NH_2 , R^7 or R^8 or R^{9a} must not be H; and

in case that -W- is cis-CH=CH- or trans-CH=CH-, R⁶ must not be NH₂ or SH;

Attorney Docket No. 014.0005-US00

Application No.: 10/593,259

or the pharmaceutically acceptable salts, esters, or amides of the compounds of formula (C) or (D).

- 12. (Previously Presented) A pharmaceutical composition of claim 11 wherein the at least one compound is a compound of formula (C).
- 13. (Previously Presented) A pharmaceutical composition of claim 11 wherein the at least one compound is a compound of formula (D).
- 14. (Withdrawn Previously Presented) A method of inhibiting the binding of P-selectin, L-selectin or E-selectin to sLe^x or sLe^a and tyrosinesulfate residues in a patient comprising the administration of a compound having the structure of formula (C) or (D) as defined in claim 11.
- 15. (Withdrawn Previously Presented) A method of treating, diagnosing, or preventing inflammatory disorders in a patient comprising the administration of a compound having the structure of formula (C) or (D) as defined in claim 11.
- 16. (Withdrawn Previously Presented) A method of treating Chronic Obstructive Pulmonary Disease (COPD), acute respiratory distress syndrome (ARDS), Crohn's disease, septic shock, sepsis, chronic inflammatory diseases, psoriasis, atopic dermatitis, rheumatoid arthritis, reperfusion injury that occurs following heart attacks, strokes, atherosclerosis, organ transplants, traumatic shock, multi-organ failure, or an autoimmune disease selected from multiple sclerosis, asthma, and inflammatory bowel disease in a patient comprising the administration of a compound having the structure of formula (C) or (D) as defined in claim 11.